These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9755880)

  • 1. Individual bioequivalence: attractive in principle, difficult in practice.
    Endrenyi L; Amidon GL; Midha KK; Skelly JP
    Pharm Res; 1998 Sep; 15(9):1321-5. PubMed ID: 9755880
    [No Abstract]   [Full Text] [Related]  

  • 2. Update to the PhRMA perspective on population and individual bioequivalence.
    Barrett JS; Batra V; Chow A; Cook J; Gould AL; Heller AH; Lo MW; Patterson SD; Smith BP; Stritar JA; Vega JM; Zariffa N
    J Clin Pharmacol; 2000 Jun; 40(6):571-2. PubMed ID: 10868306
    [No Abstract]   [Full Text] [Related]  

  • 3. Bioequivalence: the regulatory career of a pharmaceutical concept.
    Carpenter D; Tobbell DA
    Bull Hist Med; 2011; 85(1):93-131. PubMed ID: 21551918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The U.S. draft guidance regarding population and individual bioequivalence approaches: comments by a research-based pharmaceutical company.
    Hauschke D; Steinijans VW
    Stat Med; 2000 Oct; 19(20):2769-74. PubMed ID: 11033574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges and opportunities in establishing scientific and regulatory standards for assuring therapeutic equivalence of modified-release products: workshop summary report.
    Chen ML; Shah VP; Ganes D; Midha KK; Caro J; Nambiar P; Rocci ML; Thombre AG; Abrahamsson B; Conner D; Davit B; Fackler P; Farrell C; Gupta S; Katz R; Mehta M; Preskorn SH; Sanderink G; Stavchansky S; Temple R; Wang Y; Winkle H; Yu L
    Eur J Pharm Sci; 2010 May; 40(2):148-53. PubMed ID: 20347972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consumer's risk in the EMA and FDA regulatory approaches for bioequivalence in highly variable drugs.
    Muñoz J; Alcaide D; Ocaña J
    Stat Med; 2016 May; 35(12):1933-43. PubMed ID: 26707698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability and bioequivalence requirements: abbreviated applications. Final Rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Dec; 67(244):77668-75. PubMed ID: 12492102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individual bioequivalence revisited.
    Chen ML; Lesko LJ
    Clin Pharmacokinet; 2001; 40(10):701-6. PubMed ID: 11707058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mean difference vs. variability reduction: tradeoffs in aggregate measures for individual bioequivalence. FDA Individual Bioequivalence Working Group.
    Hauck WW; Chen ML; Hyslop T; Patnaik R; Schuirmann D; Williams R
    Int J Clin Pharmacol Ther; 1996 Dec; 34(12):535-41. PubMed ID: 8996848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subject-by-formulation interaction in bioequivalence: conceptual and statistical issues. FDA Population/Individual Bioequivalence Working Group. Food and Drug Administration.
    Hauck WW; Hyslop T; Chen ML; Patnaik R; Williams RL
    Pharm Res; 2000 Apr; 17(4):375-80. PubMed ID: 10870978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug bioequivalence. Recommendations from the Drug Bioequivalence Study Panel to the Office of Technology Assessment, Congress of the United States.
    J Pharmacokinet Biopharm; 1974 Oct; 2(5):433-66. PubMed ID: 4452945
    [No Abstract]   [Full Text] [Related]  

  • 12. Generic drugs and the elderly.
    Lasagna L
    J Am Geriatr Soc; 1983 Sep; 31(9):571-2. PubMed ID: 6886286
    [No Abstract]   [Full Text] [Related]  

  • 13. Generics Substitution, Bioequivalence Standards, and International Oversight: Complex Issues Facing the FDA.
    Bate R; Mathur A; Lever HM; Thakur D; Graedon J; Cooperman T; Mason P; Fox ER
    Trends Pharmacol Sci; 2016 Mar; 37(3):184-191. PubMed ID: 26687297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The bioequivalence of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing individual bioequivalence using the structural equation model.
    Carrasco JL; Jover L
    Stat Med; 2003 Mar; 22(6):901-12. PubMed ID: 12627408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirements for submission of bioequivalence data; final rule. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA moves closer to new requirements for NTI drugs.
    Traynor K
    Am J Health Syst Pharm; 2011 Sep; 68(17):1568-9, 1570. PubMed ID: 21856797
    [No Abstract]   [Full Text] [Related]  

  • 18. Bioavailability and Bioequivalence Aspects of Oral Modified-Release Drug Products.
    Wang R; Conner DP; Li BV
    AAPS J; 2017 Mar; 19(2):360-366. PubMed ID: 28004346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The bootstrap in bioequivalence studies.
    Pigeot I; Hauschke D; Shao J
    J Biopharm Stat; 2011 Nov; 21(6):1126-39. PubMed ID: 22023681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From the Food and Drug Administration.
    Nightingale SL
    JAMA; 1991 Mar; 265(10):1229. PubMed ID: 1995961
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.